Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NXG6
UPID:
P4HTM_HUMAN
Alternative names:
Hypoxia-inducible factor prolyl hydroxylase 4
Alternative UPACC:
Q9NXG6; Q6PAG6; Q8TCJ9; Q8WV55; Q96F22; Q9BW77
Background:
Transmembrane prolyl 4-hydroxylase, also known as Hypoxia-inducible factor prolyl hydroxylase 4, plays a pivotal role in oxygen sensing within cells. It catalyzes the formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins, targeting HIF1A at 'Pro-402' and 'Pro-564'. This enzyme may act as a cellular oxygen sensor, facilitating the degradation of HIF under normoxic conditions via the von Hippel-Lindau ubiquitination complex.
Therapeutic significance:
The enzyme's involvement in a neurodevelopmental disorder characterized by hypotonia, hyperventilation, impaired intellectual development, and other symptoms underscores its therapeutic significance. Understanding the role of Transmembrane prolyl 4-hydroxylase could open doors to potential therapeutic strategies for treating this complex condition.